Poziotinib NDA accepted for FDA review in previously treated patients with NSCLC harboring HER2 exon 20 insertion mutations, PDUFA date November 24, 2022 Positive poziotinib results in treatment naïve ...
Thank you for standing by, and welcome to the Spectrum Pharmaceuticals fourth quarter 2021 earnings call. [Operator instructions] As a reminder, today's program may be recorded. I would now like to ...
HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will ...
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback